For the quarter ending 2026-03-31, CRSP had $72,236K increase in cash & cash equivalents over the period. -$109,401K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -122,931 | -130,613 | -106,441 | -344,545 |
| Depreciation and amortization | 4,319 | 5,661 | 4,433 | 9,385 |
| Equity-based compensation | 16,324 | 18,076 | 16,604 | 37,819 |
| Other non-cash items, net | -8,800 | 8,314 | 10,139 | 5,075 |
| Acquired in-process research and development | - | 0 | 0 | 96,253 |
| Accounts receivable | 0 | 0 | 0 | -25,000 |
| Prepaid expenses and other assets | 247 | -3,852 | -212 | 727 |
| Accounts payable and accrued expenses | -13,015 | 4,421 | 12,175 | 28,298 |
| Deferred revenue | -427 | 2,153 | -834 | -1,716 |
| Operating lease assets and liabilities | -1,521 | -1,343 | -1,446 | -2,421 |
| Other liabilities, net | -199 | 13,554 | 802 | -10,098 |
| Net cash used in operating activities | -108,897 | -92,553 | -84,634 | -167,827 |
| Purchase of property, plant and equipment | 504 | 517 | 74 | 323 |
| Purchase of in-process research and development | - | 0 | 0 | 25,000 |
| Investment in equity securities | 4,615 | 0 | 0 | 9,700 |
| Sale of equity securities | - | 702 | - | - |
| Purchases of marketable securities | 746,089 | 262,973 | 334,086 | 411,111 |
| Maturities of marketable securities | 192,759 | 299,987 | 214,934 | 496,356 |
| Sales of marketable securities | 147,706 | - | - | - |
| Net cash used in investing activities | -410,743 | 37,199 | -119,226 | 50,222 |
| Proceeds from issuance of the notes | 600,000 | - | - | - |
| Issuance costs and discounts associated with the notes | 13,528 | - | - | - |
| (payments) proceeds from issuance of common shares, net of issuance costs | -722 | 111,491 | 278,105 | 8,494 |
| Proceeds from exercise of options and espp contributions, net of issuance costs | 6,158 | 4,923 | 18,661 | 4,352 |
| Net cash provided by financing activities | 591,908 | 116,414 | 296,766 | 12,846 |
| Effect of exchange rate changes on cash | -32 | 1 | -27 | 121 |
| Increase (decrease) in cash | 72,236 | 61,061 | 92,879 | -104,638 |
| Cash, cash equivalents and restricted cash, beginning of period | 359,078 | 298,017 | 309,776 | - |
| Cash, cash equivalents and restricted cash, end of period | 431,314 | 359,078 | 298,017 | - |
CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP)